Want to see SIBN full AI Analyst Report?
SIBN Stock Chart & Stats
$14.09
$0.02(0.14%)
At close: 4:00 PM EST
$14.09
$0.02(0.14%)
Day’s Range― - ―
52-Week Range$11.48 - $21.89
Previous CloseN/A
Volume50.81K
Average Volume (3M)648.60K
Market Cap
$770.79M
Enterprise Value$453.48
Total Cash (Recent Filing)$144.68M
Total Debt (Recent Filing)$7.35M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding44,349,280
10 Day Avg. Volume524,959
30 Day Avg. Volume648,599
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.25Price Target Upside65.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$231.64M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently high gross margins (~79–80%) reflect strong unit economics and pricing power for the iFuse implant system. Durable contribution margins provide room for scalable operating leverage as procedures and territories grow, helping sustain profitability as the business scales.
Low Leverage / Strong Balance SheetVery low debt and substantial equity reduce refinancing and solvency risk, giving management flexibility to fund product launches, R&D and commercial expansion from liquidity rather than urgent external financing. This supports multi-quarter investment plans and strategic optionality.
Durable Physician AdoptionSustained and broadening physician adoption demonstrates effective commercial execution and stickiness of the therapy. High active surgeon growth and territory productivity suggest repeat procedure demand and embedded clinical practice patterns, supporting durable volume growth.
Bears Say
GAAP Losses & Negative Free Cash FlowOngoing GAAP net losses and negative free cash flow mean the company has not yet reached self-funded profitability. Continued investments and seasonal cash variability could prolong cash consumption, forcing reliance on existing cash reserves and constraining reinvestment flexibility.
Execution Risk On Partner RampMaterial revenue upside is contingent on a phased Smith & Nephew rollout and partner training/commercial capacity. Delays in onboarding, hospital approvals, or partner execution can defer expected volume and margin benefits, creating multi-quarter timing risk to achieving guidance.
ASP Pressure From Mix ShiftsManagement now assumes low-single-digit ASP degradation as trauma and less-implant procedures become a larger mix. Reduced average selling price per procedure limits revenue per case upside, which can cap topline leverage even as procedure counts rise, pressuring revenue growth profile.
SI-Bone News
SIBN FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was $11.48 and its highest was $21.89 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is $770.79M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Aug 10, 2026 which is in 21 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on May 11, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.088.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.15.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,349,280 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 19.724%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in SIBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.25 (65.01% Upside)
$23.25 (65.01% Upside)
Blogger Sentiment
Bullish
SIBN Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 741.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $507.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.93%
12-Months-Change
Fundamentals
Return on Equity
-9.56%
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
SIBN Stock 12 Month Forecast
Average Price Target
$23.25
▲(65.01% Upside)
Technical Analysis
Ownership Overview
5.15% Insiders
26.49% Mutual Funds
46.01% Other Institutional Investors
10.11% Public Companies and
Individual Investors